From WikiMD

Ravulizumab (ALXN1210) (INN:[1] Ultomiris) is a humanized monoclonal antibody designed for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

This drug was developed by Alexion Pharmaceuticals, Inc.[2]

It was approved by the US Food and Drug Administration in December 2018.[3] In April 2019, the European CHMP of EMA recommended the granting of a conditional marketing authorisation for ravulizumab.[4]


W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Ravulizumab">Ravulizumab</a>

  • Individual results may vary for weight loss from our sponsors.